Non-interventional Study With Ectoin Containing and/or Decongesting Nasal Spray in Patients With Rhinosinusitis
Keywords
Abstract
Description
The current non-interventional study aims to investigate the efficacy and tolerability of Ectoin containing Rhinosinusitis Nasal Spray (SNS01) in patients with acute rhinosinusitis. Patients can chose one of three treatment options: a) Ectoin containing Rhinosinusitis Nasal Spray (SNS01), b) decongestant Xylometazoline-containing nasal spray or c) Ectoin containing Rhinosinusitis Nasal Spray (SNS01) and a decongestant Xylometazoline-containing nasal spray.
Efficacy will be studied by documentation of the following symptoms:
- oedema, redness (assessed by rhinoscopy)
- nasal obstruction, nasal secretion, headache/face pain, loss of sense of smell/taste
- sore throat, cough
In parallel, participating patients will document their symptoms and the their quality of life over the entire study duration in patient diaries.
Patients of both genders aged 6 years and above can take part in the study if diagnosed with acute viral rhinosinusitis. The assignment of a patient to a particular treatment is not decided in advance but falls within current practice, and is clearly separated from the decision to include the patient into the study.
Study therapy will be applied in accordance with the respective instructions for use.
Study duration is 7-14 days, depending on the improvement of symptoms. At the end of the study, both the investigators and the patients are asked to judge the efficacy and tolerability of the treatments.
Dates
Last Verified: | 10/31/2018 |
First Submitted: | 09/30/2018 |
Estimated Enrollment Submitted: | 09/30/2018 |
First Posted: | 10/02/2018 |
Last Update Submitted: | 07/08/2019 |
Last Update Posted: | 07/09/2019 |
Actual Study Start Date: | 09/30/2018 |
Estimated Primary Completion Date: | 04/14/2019 |
Estimated Study Completion Date: | 04/14/2019 |
Condition or disease
Intervention/treatment
Drug: Xylometazoline Nasal Spray
Device: Ectoin Rhinosinusitis Nasal Spray
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Ectoin Rhinosinusitis Nasal Spray application of 1-2 sprays of SNS01 into each nostril several times a day | |
Xylometazoline nasal spray 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day | |
Xylometazoline + Ectoin Nasal Spray Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day |
Eligibility Criteria
Ages Eligible for Study | 6 Years To 6 Years |
Sexes Eligible for Study | All |
Sampling method | Non-Probability Sample |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - patients with acute viral rhinosinusitis - presence of common cold symptoms Exclusion Criteria: - contraindications in accordance with instructions for use - acute bacterial rhinosinusitis - chronic rhinosinusitis |
Outcome
Primary Outcome Measures
1. Physicians' assessment of change of intensity of rhinosinusitis symptoms [day 0 and day 7 and (if necessary, depending on study duration) and on day 14]
Secondary Outcome Measures
1. Physicians' assessment of general well-being of patients [day 0 and day 7 and day 14 (if necessary, depending on study duration)]
2. Patients' assessment of intensity of symptoms and their influence on quality of life [7 to 14 days (depending on study duration)]
3. Investigators' and patients' assessment of efficacy of treatments [once on day 7 or day 14 (depending on study duration)]
4. Assessment of the tolerability of treatments [once on day 7 or once on day 14 of treatment (depending on study duration)]
5. Incidence of adverse events/serious adverse events [7 to 14 days (depending on study duration)]